Catherine Sabatos-Peyton
Chief Executive Officer Larkspur Biosciences
Seminars
Tuesday 27th October 2026
Targeting Cancer Fitness: PIP4K2C Degrader LRK-4189 Enters the Clinic for MSS CRC & Beyond
11:30 am
- Developing first-in-class cereblon-based heterobifunctional degraders that target cancer fitness, the stress adaptations cancer cells use to proliferate, invade tissue, and escape immune detection
- Our FIH study of LRK-4189 was a single-ascending dose study in healthy volunteers, a strategic approach to rapidly identifying a pharmacologically active dose
- Emergent data support progression of LRK-4189 in MSS CRC through characterization of the tumor genetics and molecular pathways that drive dependency on PIP4K2C
